Malin Hultcrantz, MD PhD¹, David Kleinman, MD^2*, Pavandeep Ghataorhe, MD, PhD^3*, Astrid McKeown, PhD^3*, Wei He, PhD^4*, Thomas Ling, BSc^3*, Roxanne C Jewell, PhD^5*, Joseph Brunner, MS^6*, Julie Byrne, PhD^6*, Laurie Eliason^6*, Emma Scott, MD^6* and Joanna Opalinska, MD⁶

¹Memorial Sloan Kettering Cancer Center, New York, NY
²University of Rochester, Rochester, NY
³GlaxoSmithKline, London, United Kingdom
⁴GlaxoSmithKline, Cambridge, MA
⁵GlaxoSmithKline, Research Triangle Park, NC
⁶GlaxoSmithKline, Upper Providence, PA

Saad Z. Usmani, MD MBA FACP¹, Shaji K Kumar, MD², Torben Plesner, MD³, Robert Z. Orlowski⁴, Philippe Moreau, MD, PhD^5*, Nizar J. Bahlis, MD⁶, Supratik Basu^7*, Hareth Nahi^8*, Cyrille Hulin^9*, Hang Quach, FRACP, FRCPA¹⁰, Hartmut Goldschmidt¹¹, Michael E. O'Dwyer, MD¹², Aurore Perrot^13*, Chris P. Venner¹⁴, Katja Weisel^15*, Joseph R. Mace^16*, Noopur S. Raje, MD¹⁷, Mourad Tiab^18*, Margaret Macro^19*, Laurent Frenzel^20*, Xavier Leleu, MD²¹, Huiling Pei, PhD^22*, Rian Van Rampelbergh^23*, Brenda Tromp²⁴, Maria Delioukina^25* and Thierry Facon^26*

¹Levine Cancer Institute, New York, NY
²Department of Hematology, Mayo Clinic Rochester, Rochester, MN
³Vejle Hospital and University of Southern Denmark, Vejle, Denmark
⁴Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Hematology, University Hospital Hôtel-Dieu, Nantes, France
⁶Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
⁷The Royal Wolverhampton Hospitals NHS Trust and University of Wolverhampton, Wolverhampton, United Kingdom
⁸Karolinska University Hospital at Huddinge, Karolinska Institute, Stockholm, Sweden
⁹Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
¹⁰University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC, Australia
¹¹University Hospital Heidelberg, Heidelberg, Germany
¹²Department of Medicine/Haematology, NUI, Galway, Ireland
¹³CHU de Toulouse, IUCT-O, Université de Toulouse, Toulouse, France
¹⁴University of Alberta, Edmonton, AB, Canada
¹⁵Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
¹⁶Florida Cancer Specialists, St. Petersburg, FL
¹⁷Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA
¹⁸CHD Vendée, La Roche sur Yon, France
¹⁹Centre Hospitalier Universitaire (CHU) de Caen, Caen, France
²⁰Department of Clinical Haematology, Hopital Necker-Enfants Malades, Paris, France
²¹CHU Poitiers, Hôpital la Milétrie, Poitiers, France
²²Janssen Research & Development, LLC, Titusville, NJ
²³Janssen Research & Development, Beerse, Belgium
²⁴Janssen Research & Development, Leiden, Netherlands
²⁵Janssen Research & Development, LLC, Spring House, PA
²⁶University of Lille, CHU Lille, Lille, France

Paula Rodriguez-Otero^1*, Bhagirathbhai Dholaria, MBBS², Elham Askari^3*, Donna E. Reece⁴, Niels W.C.J. van de Donk⁵, Ajai Chari, MD^6*, Hartmut Goldschmidt⁷, Amrita Y. Krishnan, MD⁸, Thomas Martin, MD⁹, Maria-Victoria Mateos¹⁰, Daniel Morillo Giles^3*, Cesar Rodriguez¹¹, Laura Rosinol^12*, Jesús F. San-Miguel¹, Anna Sureda¹³, Ralph Wäsch¹⁴, Katja Weisel^15*, Raluca I. Verona^16*, Shun Xin Wang Lin^16*, Thomas J. Prior^16*, Brendan M. Weiss¹⁶, Mark Wade^16*, Jenna D. Goldberg^17*, Albert Oriol^18* and Parameswaran Hari¹⁹

¹Clinica Universidad de Navarra, Navarra, Spain
²Vanderbilt University Medical Center, Nashville, TN
³Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
⁴Princess Margaret Cancer Centre, Toronto, ON, Canada
⁵Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
⁶Mount Sinai School of Medicine, New York, NY
⁷University Hospital Heidelberg and National Center of Tumor Diseases, Heidelberg, Germany
⁸City of Hope Comprehensive Cancer Center, Duarte, CA
⁹University of California San Francisco, San Francisco, CA
¹⁰University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
¹¹Wake Forest University School of Medicine, Winston-Salem, NC
¹²Institute of Hematology and Oncology, Hematology Department, IDIBAPS Hospital Clínic University of Barcelona, Barcelona, Spain
¹³Institut Català d'Oncologia – Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
¹⁴Freiburg University Medical Center, Frieburg, Germany
¹⁵University Medical Center Hamburg-Eppendorf, Hamburg, Germany
¹⁶Janssen Research & Development, Spring House, PA
¹⁷Janssen Research & Development, Raritan, NJ
¹⁸Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
¹⁹Medical College of Wisconsin, Milwaukee, WI

Jianxiang Wang, MD¹, Weijun Fu, PhD^2*, Soo-Mee Bang, MD, PhD³, Honghui Huang, PhD, MD^4*, Kihyun Kim^5*, Wei Li, MD^6*, Gang An, MD, PhD^1*, Je-Jung Lee, MD, PhD⁷, Zhen Cai^8*, Jie Jin, MD⁸, Yafei Wang^9*, CS Chim, MD, PhD, BMBS¹⁰, Paula Rodriguez-Otero^11*, Anna Marina Liberati, MD¹², Hiroyuki Takamatsu, MD, PhD¹³, Jae Hoon Lee, MD, PhD¹⁴, Meletios A. Dimopoulos, MD¹⁵, Susan Wroblewski, PhD^16*, Robin Carson, MD, BA¹⁶, Ming Qi, MD, PhD¹⁶, Jianping Wang^17*, Yang Song^18*, Bin Jia^19*, Xue Yang^19*, Wenyu Liu^18*, Yunan Li^20*, Renyi Zhang^21* and Jian Hou^4*

¹Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
²Shanghai Changzheng Hospital, Shanghai, China
³Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South)
⁴Department of Hematology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
⁵Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
⁶Department of Hematology at the Oncology Center, The First Hospital of Jilin University, Changchun, China
⁷Department of Hematology-Oncology, Chonnam National University Medical School, Hwasun, Jeollanamdo, Korea, Republic of (South)
⁸The First Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, Zhejiang, China
⁹Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
¹⁰Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong
¹¹Clínica Universidad de Navarra, Pamplona, Spain
¹²Azienda Ospedaliera "Santa Maria", Terni, Italy
¹³Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan
¹⁴Gachon University Gil Medical Center, Incheon, Korea, Republic of (South)
¹⁵National and Kapodistrian University of Athens, Athens, Greece
¹⁶Janssen Research & Development, LLC, Spring House, PA
¹⁷Janssen Research & Development, LLC, Raritan, NJ
¹⁸Janssen Research & Development, LLC, Beijing, China
¹⁹Janssen Research & Development, LLC, Shanghai, China
²⁰Medical Affairs, Xian Janssen Pharmaceutical Ltd., Beijing, China
²¹Medical Affairs, Xian Janssen Pharmaceutical Ltd., Shanghai, China

Omar Nadeem, MD¹, Robert A. Redd, MS^2*, Michael Z. Koontz, MD³, Jeffrey V. Matous, MD⁴, Andrew J. Yee, MD⁵, Jeffrey A. Zonder, MD ⁶, Andrew Kin, MD⁷, Jacalyn Rosenblatt, MD⁸, Julia Prescott, MSN, NP^9*, Kelsey Tague^10*, Veronica Romines^10*, Meredith Bertoni^10*, Amada Metivier^10*, Rebekah Medina^10*, Alexandra Savell, BS^9*, Houry Leblebjian, PharmD, BCOP^11*, Alexandra Distaso^12*, Clifton C Mo, MD^12*, Jacob P. Laubach, MD¹³, Adam S. Sperling, MD, PhD¹⁴, Paul G. Richardson, MD¹⁵ and Irene M. Ghobrial, MD¹⁶

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
³Pacific Cancer Care, Morgan Hill, CA
⁴Sarah Cannon Research Institute, Colorado Blood Cancer Institute, Denver, CO
⁵Massachusetts General Hospital Cancer Center, Boston, MA
⁶Karmanos Cancer Institute, Detroit, MI
⁷Department of Oncology, Blood and Marrow Stem Cell Transplant Program, Karmanos Cancer Institute/ Wayne State University, Detroit, MI
⁸Beth Israel Deaconess Medical Center, Boston, MA
⁹Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹⁰Dana-Farber Cancer Institute, Boston
¹¹Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA
¹²Dana-Farber Cancer Institute, Boston, MA
¹³The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Newton, MA
¹⁴Division of Hematology, Dana-Farber Cancer Institute, Boston, MA
¹⁵Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
¹⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Omar Nadeem, MD^1,2, Robert A. Redd, MS^3*, Peter Barth, MD⁴, Clifton C Mo, MD^5*, Jacob P. Laubach, MD⁶, Giada Bianchi, MD⁷, Trevor J. Bayliss, MD^8*, Vaishali Sanchorawala, MD⁹, Leyla Shune, MD¹⁰, Alexandra Distaso^5*, Virginia Dalton, MS, APRN^11*, Mary McKenney, NP^11*, Sarah Patches^12*, Isabella Hou^5*, Lindsay Issokson^13*, Anna Barrell^13*, Kelly Masone, BA^5*, Adam S. Sperling, MD, PhD¹⁴, Nikhil C. Munshi, MD, PhD¹⁵, Irene M. Ghobrial, MD^2,16, Kenneth C. Anderson, MD¹⁷ and Paul G. Richardson, MD¹⁸

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Harvard Medical School, Boston, MA
³Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁴Department of Medicine, Alpert Medical School of Brown University, Providence, RI
⁵Dana-Farber Cancer Institute, Boston, MA
⁶The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Newton, MA
⁷Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA
⁸Berkshire Health Services, Pittsfield, MA
⁹Amyloidosis Center, Boston Medical Center Corporation, Boston, MA
¹⁰Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
¹¹The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹²Dana Farber Cancer Insititute, Boston, MA
¹³Dana-Farber Cancer Institute, Boston
¹⁴Division of Hematology, Dana-Farber Cancer Institute, Boston, MA
¹⁵Dana-Farber Cancer Institute, Harvard Medical School, Boston
¹⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁷Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
¹⁸Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA

Suzanne Lentzsch, MD, PhD^1*, Brea Lipe, MD², Sascha A. Tuchman, MD³, Nizar J. Bahlis, MD⁴, William I. Bensinger, MD^5*, Michael Sebag, MD, PhD⁶, Heather J. Sutherland, MD, PhD, FRCPC⁷, Jorge Monge, MD^8*, Cristina J. Gasparetto, MD^9*, Muhamed Baljevic, MD¹⁰, Natalie S. Callander, MD¹¹, Christopher P. Venner, MD^12*, Darrell J. White, MD¹³, Rami Kotb, MD¹⁴, Christine I. Chen, MD¹⁵, Gary J. Schiller, MD¹⁶, Sumit Madan, MD^17*, Richard Leblanc, MD, FRCPC¹⁸, Andrew DeCastro, PhD^19*, Ohad S. Bentur, MD MHA^19*, Jatin J. Shah, MD^19*, Dane R. Van Domelen, PhD^19*, Michael G. Kauffman, MD, PhD¹⁹, Sharon Shacham, PhD, MBA^19* and Noa Biran, MD²⁰

¹Multiple Myeloma and Amyloidosis Service, Columbia University Medical Center, New York, NY
²Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
³Department of Medicine, Division of Hematology, University of North Carolina, Durham, NC
⁴Southern Alberta Cancer Research Institute, Calgary, AB, Canada
⁵Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
⁶Division of Hematology, McGill University Health Centre, Montreal, QC, Canada
⁷Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada
⁸Weill Cornell Medicine, New York, NY
⁹Duke University Medical Center, Durham, NC
¹⁰University of Nebraska Medical Center, Omaha, NE
¹¹Carbone Cancer Center, University of Wisconsin, Madison, WI
¹²Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
¹³Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada
¹⁴Medical Oncology and Hematology, Cancer Care Manitoba, Winnipeg, MB, Canada
¹⁵Department of M, Princess Margaret Cancer Centre, Toronto, ON, Canada
¹⁶University of California Los Angeles, Los Angeles, CA
¹⁷Banner MD Anderson Cancer Center, Gilbert, AZ
¹⁸Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada
¹⁹Karyopharm Therapeutics Inc., Newton, MA
²⁰John Theurer Cancer Center, Hackensack Meridian Health, Hackensack University Medical Center, Hackensack, NJ

Sikander Ailawadhi, MD¹, Patrick Stiff, MD², Emad Ibrahim, MBBCh, MD³, Damian J. Green, MD⁴, Brea Lipe, MD⁵, Elizabeth H. Cull, MD⁶, Natalie S. Callander, MD⁷, John Friend, MD⁸, Jarrod Longcor^8* and Kate Oliver, BS^8*

¹Division of hematology, Mayo Clinic, Jacksonville, FL
²Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL
³Redlands Community Hospital, Redlands, CA
⁴Fred Hutchinson Cancer Research Center, Seattle, WA
⁵Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
⁶Cancer Institute, Prisma Health, Piedmont, SC
⁷University of Wisconsin, Madison, WI
⁸Cellectar Biosciences, Florham Park, NJ

Suzanne Trudel, MD¹, Arleigh McCurdy, MD, MPH², Heather J. Sutherland, MD, PhD, FRCPC³, Martha L Louzada, MD, MSc⁴, Christopher P. Venner, MD^5*, Hira S Mian, MD⁶, Rami Kotb, MD⁷, Ibraheem Othman, MD, MSc, PhD⁸, Fernando Camacho, PhD^9*, Engin Gul, BSc, MBA^10*, Donna E. Reece¹¹, Darrell J White, MD¹² and Molei Fu, MSc^9*

¹Princess Margaret Cancer Centre, Toronto, ON, Canada
²Department of Medicine, Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada
³Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada
⁴University of Western Ontario, London Health Sciences Centre, London, ON, Canada
⁵Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
⁶Juravinski Cancer Centre (Hamilton-CCO), Hamilton, ON, Canada
⁷CancerCare Manitoba, Winnipeg, MB, Canada
⁸Allan Blair Cancer Centre, Regina, SK, CAN
⁹Canadian Myeloma Research Group (formerly MCRN), Vaughan, ON, Canada
¹⁰Canadian Myeloma Research Group (CMRG), Toronto, ON, Canada
¹¹Canadian Myeloma Research Group (formerly MCRN), Toronto, Canada
¹²Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

Sumit Madan, MD^1*, Al-Ola Abdallah, MD², Andrew J. Cowan, MD³, William I. Bensinger, MD^4,5*, Jens Hillengass⁶, Xavier Leleu, MD⁷, Eva Medvedova, MD^8*, Caitlin Costello, MD⁹, Brea Lipe, MD¹⁰, Henning Schade, MD^11*, Rajneesh Nath, MD^12* and Liping Laura Sun, PhD^12*

¹Banner MD Anderson Cancer Center, Gilbert, AZ
²Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
³University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
⁴Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
⁵Fred Hutchinson Cancer Rsch. Ctr., Seattle, WA
⁶Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁷Department of Hematology, CHU Poitiers – Hôpital la Milétrie, Poitiers, France
⁸Oregon Health & Science University, Portland, OR
⁹UC San Diego Health, Moores Cancer Center, La Jolla, CA
¹⁰Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
¹¹Colorado Blood Cancer Institute, Denver, CO
¹²Harpoon Therapeutics, South San Francisco, CA

Aurore Perrot, MD, PhD^1*, Thierry Facon^2*, Shaji K Kumar, MD³, Torben Plesner, MD⁴, Robert Z. Orlowski⁵, Philippe Moreau, MD, PhD^6*, Nizar J. Bahlis, MD⁷, Supratik Basu^8*, Hareth Nahi^9*, Cyrille Hulin^10*, Hang Quach, FRACP, FRCPA¹¹, Hartmut Goldschmidt¹², Michael E. O'Dwyer, MD¹³, Chris P. Venner¹⁴, Katja Weisel^15*, Joseph R. Mace^16*, Noopur S. Raje, MD¹⁷, Mourad Tiab^18*, Magaret Macro^19*, Laurent Frenzel, MD, PhD²⁰, Xavier Leleu, MD²¹, Kevin Liu^22*, John Fastenau^23*, Katharine S. Gries^23*, Kai Fai Ho^24*, Pankaj Mistry^25*, Brenda Tromp²⁶, Maria Delioukina^27*, Jessica Vermeulen²⁶ and Saad Z. Usmani, MD MBA FACP²⁸

¹CHU de Toulouse, IUCT-O, Université de Toulouse, Toulouse, France
²University of Lille, CHU Lille, Lille, France
³Mayo Clinic, Rochester, MN
⁴Vejle Hospital, Vejle, Denmark
⁵The University of Texas MD Anderson Cancer Center, Houston, TX
⁶University Hospital Hôtel-Dieu, Nantes, Nantes, France
⁷Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
⁸The Royal Wolverhampton NHS Trust and University of Wolverhampton, Wolverhampton, United Kingdom
⁹Karolinska University Hospital at Huddinge, Karolinska Institute, Stockholm, Sweden
¹⁰Hôpital Haut Leveque, University Hospital, Pessac, France
¹¹St. Vincent’s Hospital, Melbourne, VIC, Australia
¹²University Hospital Heidelberg and National Center of Tumor Diseases, Heidelberg, Germany
¹³National University of Ireland, Galway, Ireland
¹⁴University of Alberta, Edmonton, AB, Canada
¹⁵University Medical Center Hamburg-Eppendorf, Hamburg, Germany
¹⁶Florida Cancer Specialists & Research Institute, St. Petersburg, FL
¹⁷Massachusetts General Hospital Cancer Center, Boston, MA
¹⁸Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France
¹⁹Haematology Department, Caen University Hospital, Caen, France
²⁰Assistance Publique–Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France
²¹Service D'Hématologie Et Thérapie Cellulaire, Poitiers, France
²²Janssen Global Services, Raritan, NJ
²³Janssen Research & Development, Raritan, NJ
²⁴STAT-TU, Inc, Toronto, ON, Canada
²⁵Janssen Research & Development, High Wycombe, United Kingdom
²⁶Janssen Research & Development, Leiden, Netherlands
²⁷Janssen Research & Development, LLC, Spring House, PA
²⁸Levine Cancer Institute/Atrium Health, Charlotte, NC

Meletios A. Dimopoulos, MD¹, S. Vincent Rajkumar, MD^2*, Sagar Lonial, MD, FACP³, Wee-Joo Chng⁴, Shinsuke Iida, MD, PhD⁵, Maria-Victoria Mateos⁶, Gareth J. Morgan, MD, PhD⁷, Arun Kumar^8*, Kaveri Suryanarayan, MD^8*, Alexander Vorog, MD^9*, Andrew Fergus^8* and Richard Labotka, MD⁸

¹National and Kapodistrian University of Athens, Athens, Greece
²Division of Hematology, Mayo Clinic, Rochester, MN
³Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University Medical School, Emory University, Atlanta, GA
⁴Department of Hematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore
⁵Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
⁶University Hospital of Salamanca, CIC, IBMCC, Salamanca, Spain
⁷Perlmutter Cancer Center, NYU Langone Health, New York, NY
⁸Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
⁹Takeda Development Center Americas, Inc., Lexington, MA

Meral Beksac, MD¹, Tulin Tuglular, MD^2*, Ali Unal, MD³, Michele Cavo, MD, PhD^4*, Francesca Gay, MD, PhD⁵, Eirini Katodritou, MD^6*, Guner Hayri Ozsan, MD^7*, Guldane Cengiz, MD^1*, Omur Gokmen Sevindik, MD¹, Serena Merante, MD^8*, Kyriaki Manousou, MSc^9*, Pieter Sonneveld¹⁰ and Evangelos Terpos, MD, PhD¹¹

¹Department of Hematology, Ankara University Faculty Of Medicine Cebeci Hospital, Ankara, Turkey
²Department of Internal Medicine, Marmara University, Istanbul, Turkey
³Department of Hematology, Faculty of Medicine, Erciyes University, Melikgazi, Kayseri, Turkey
⁴Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
⁵University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
⁶Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece
⁷Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Izmir, Turkey
⁸European Myeloma Network, Pavia, Italy
⁹Health Data Specialists, Dublin, Ireland
¹⁰Erasmus University Medical Center, Rotterdam, Netherlands
¹¹Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Stefania Stefania Mancia^1*, Annamaria Farrell, PhD^2,3*, Karen Louw, NP^2*, Erika Florendo, NP^4*, Elizabeth Aronson, NP^2*, Kiah Purcell, NP^2*, Donna D Catamero, ANP-BC, OCN, CCRC^5*, Juliet Escalon, NP^2*, Joanne Thomas, PhD, RN^6*, Annel Aponte, RN^2*, Angela Lamb, MD^2*, Diana Kirke, MD^2*, Aimee Lucas, MD^2*, Sundar Jagannath⁷, Hearn Jay Cho, MD, PhD⁸, Samir Parekh, MD⁸, Joshua Richter, MD⁹, Larysa Sanchez, MD¹⁰ and Ajai Chari, MD¹¹

¹The Mount Sinai Hospital, New York, NY
²Mount Sinai Hospital, New York, NY
³Regeneron, Terrytown, NY
⁴Tisch Cancer Institute, Mt. Sinai School of Medicine, New York, NY
⁵The Mount Sinai Medical Center, New York, NY
⁶Icahn School of Medicine At Mount Sinai, New York, NY
⁷Department of Medicine, Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY
⁸Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
⁹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
¹⁰Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
¹¹Department of Hematology and Medical Oncology, Tisch Cancer Institute, Mt. Sinai School of Medicine, New York, NY

Catherine R. Marinac, PhD¹, Robert A. Redd, MS^2*, Julia Prescott, MSN, NP^3*, Alexandra Savell, BS^3*, Courtney Igne^4*, Jacob P. Laubach, MD⁵, Adam S. Sperling, MD, PhD⁶, Aric D. Parnes, MD⁷, Houry Leblebjian, PharmD, BCOP^8*, Paul G. Richardson, MD⁹, Irene M. Ghobrial, MD^1,10 and Omar Nadeem, MD¹¹

¹The Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA
²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
³Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Dana-Farber Cancer Institute, Boston
⁵The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Newton, MA
⁶Division of Hematology, Dana-Farber Cancer Institute, Boston, MA
⁷Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA
⁸Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA
⁹Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹¹The LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA

Jian Hou

Department of Hematology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Jian Hou^1*, Weijun Fu, PhD^2*, Soo-Mee Bang, MD, PhD³, Honghui Huang, PhD, MD^1*, Kihyun Kim^4*, Wei Li, MD^5*, Gang An, MD, PhD^6*, Je-Jung Lee, MD, PhD⁷, Zhen Cai^8*, Jie Jin, MD⁸, Yafei Wang^9*, CS Chim, MD, PhD, BMBS¹⁰, Paula Rodriguez-Otero^11*, Meletios A. Dimopoulos, MD¹², Tomoaki Fujisaki, MD^13*, Jae Hoon Lee, MD, PhD¹⁴, Susan Wroblewski, PhD^15*, Robin Carson, MD, BA¹⁵, Ming Qi, MD, PhD¹⁵, Jianping Wang^16*, Yang Song^17*, Bin Jia^18*, Xue Yang^18*, Wenyu Liu^17*, Yunan Li^19*, Renyi Zhang^20* and Jianxiang Wang, MD⁶

¹Department of Hematology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
²Shanghai Changzheng Hospital, Shanghai, China
³Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of (South)
⁴Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
⁵Department of Hematology at the Oncology Center, The First Hospital of Jilin University, Changchun, China
⁶Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
⁷Department of Hematology-Oncology, Chonnam National University Medical School, Hwasun, Jeollanamdo, Korea, Republic of (South)
⁸The First Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, Zhejiang, China
⁹Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
¹⁰Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong
¹¹Clinica Universidad de Navarra, IDISNA, Navarra, Spain
¹²National and Kapodistrian University of Athens, Athens, Greece
¹³Matsuyama Red Cross Hospital, Matsuyama, Japan
¹⁴Gachon University Gil Medical Center, Incheon, Korea, Republic of (South)
¹⁵Janssen Research & Development, LLC, Spring House, PA
¹⁶Janssen Research & Development, LLC, Raritan, NJ
¹⁷Janssen Research & Development, LLC, Beijing, China
¹⁸Janssen Research & Development, LLC, Shanghai, China
¹⁹Medical Affairs, Xian Janssen Pharmaceutical Ltd., Beijing, China
²⁰Medical Affairs, Xian Janssen Pharmaceutical Ltd., Shanghai, China

Katja Weisel^1*, Meletios A. Dimopoulos, MD², Jesús San-Miguel, MD, PhD³, Agne Paner, MD⁴, Monika Engelhardt, MD⁵, Fiona Taylor^6*, Jennifer Lord-Bessen, PhD^7*, David Yao^7*, Christine Yip^8*, Mike Greenwood^8*, Jackson Tang^7* and Michele Cavo, MD, PhD^9*

¹Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
²National and Kapodistrian University of Athens School of Medicine, Athens, Greece
³Clínica Universidad de Navarra, Pamplona, Spain
⁴Rush University Medical Center, Chicago, IL
⁵University Medical Center Freiburg, Freiburg, Germany
⁶Adelphi Values, Boston, MA
⁷Bristol Myers Squibb, Princeton, NJ
⁸Adelphi Values, Bollington, United Kingdom
⁹IRCCS Azienda Ospedaliero Universitaria di Bologna, Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

Rose Turner, MBBS¹, Hang Quach, FRACP, FRCPA², Noemi Horvath, MB ChB FRACP FRCPA³, Ian H Kerridge, BA, BMed(Hons), MPhil(Cantab), FRACP, FRCPA^4*, Flora Yuen, BBiomedSc^5*, Edwin Sze-Hung Lee, MD, FRACP, FRCP, FRCPA, FRCPath^6*, Edward S. Morris, BMBS, DM⁷, Anna Kalff, MBBS, FRACP, FRCPA, PhD⁸, Krystal Bergin, MBBS, FRACP, FRCPA^8*, Shreerang Sridesai, MBBS, FRACP, FRCPA^5*, Malgorzata Gorniak, BSc^5*, Sridurga Mithraprabhu, PhD, MSc^8*, Tiffany Khong, BSc, PhD⁸, John Reynolds, PhD^8* and Andrew Spencer, MBBS, FRACP, FRCPA, DM⁸

¹Alfred Health, Abbotsford, Vic, Australia
²St Vincent's Hospital - University of Melbourne, Melbourne, Australia
³Royal Adelaide Hospital, Adelaide, Australia
⁴Royal North Shore Hospital, Sydney, Australia
⁵Alfred Health, Melbourne, Australia
⁶Canberra Hospital, Canberra, Australia
⁷Townsville Cancer Centre, Townsville, QLD, Australia
⁸Alfred Health - Monash University, Melbourne, Australia

Pieter Sonneveld¹, Sonja Zweegman², Michele Cavo, MD, PhD^3*, Kazem Nasserinejad, PhD^4*, Annemiek Broyl^1*, Rosella Troia^5*, Ludek Pour, MD^6*, Sandra Croockewit, MD^7*, Paolo Corradini, MD⁸, Gerard M.J. Bos, MD, PhD⁹, Ka Lung Wu, MD¹⁰, Jolanda Droogendijk, MD^11*, Monique C. Minnema, MD¹² and Mario Boccadoro¹³

¹Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
²Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands
³Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy
⁴HOVON data center, Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
⁵hematology, University of Torino, torino, Italy
⁶Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
⁷Radboud University Medical Centre, Nijmegen, NLD
⁸Chair of Hematology, University of Milano Istituto Nazionale Tumori, Milano, Italy
⁹Division of Hematology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands
¹⁰Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
¹¹hematology, tweesteden ziekenhuis, Tilburg, NLD
¹²Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
¹³Hematology Division, Department of Molecular Biotechnologies and Health Sciences, Cattedra Ematologia, Torino, Italy

Sueh-li Lim, MBBS, FRACP, FRCPA^1,2, John Reynolds, PhD^3,4,5,6*, Hang Quach, FRACP, FRCPA^7,8, Anna Hutchinson, FRACP, FRCPA, BMedSci, MBBS^9*, Ian H Kerridge, BA, BMed(Hons), MPhil(Cantab), FRACP, FRCPA^10,11*, Jane Estell, B.Med FRACP FRCPA¹², Wojt Janowski, BMed BSc, FRCPA, FRACP¹³, Craig Thomas Wallington-Beddoe, BSc, MBBS, MBiostat, PhD, FRACP, FRCPA^14,15*, Anna Kalff, MBBS, FRACP, FRCPA, PhD^1,2, Flora Yuen, BBiomedSc^2* and Andrew Spencer, MBBS, FRACP, FRCPA, DM^1,2

¹Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia
²Malignant Haematology & Stem Cell Transplantation Services, Alfred Health, Melbourne, VIC, Australia
³Australasian Leukaemia and Lymphoma Group (ALLG), Melbourne, VIC, Australia
⁴Alfred Health - Monash University, Melbourne, Australia
⁵Biostatistics Consulting Platform, Alfred Health and Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, VIC, Australia
⁶The Alfred and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia
⁷St. Vincent’s Hospital, Melbourne, VIC, Australia
⁸University of Melbourne, Melbourne, VIC, Australia
⁹Department of Haematology, Royal Hobart Hospital, Hobart, TAS, Australia
¹⁰Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia
¹¹University of Sydney, Sydney, NSW, Australia
¹²Haematology Department, Concord Cancer Centre, Concord Hospital, Concord, NSW, Australia
¹³Calvary Mater Newcastle, Waratah, AUS
¹⁴Department of Haematology, Flinders Medical Centre-College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Adelaide, Australia
¹⁵Flinders Medical Centre Flinders University, Adelaide, Australia

Robert Z. Orlowski¹, Sosana Delimpasi, MD^2*, Jan Straub, MD^3*, Argiris Symeonidis, MD, PhD⁴, Luděk Pour, MD^5*, Roman Hajek, MD, PhD⁶, Cyrille Touzeau, MD^7*, Viralkumar K. Bhanderi, MD^8*, Pawel J. Robak, MD PhD^9*, Jesús G. Berdeja¹⁰, Jeffrey V. Matous, MD¹¹, Lionel Karlin^12*, Sonja Zweegman¹³, Sebastian Grosicki, MD, PhD¹⁴, Andrzej Pluta, MD^15*, Suman Kambhampati, MD^16*, Kaveri Suryanarayan, MD^17*, Philip Twumasi-Ankrah^17*, Ajeeta B. Dash, PhD^17*, Richard Labotka, MD¹⁷ and Meletios A. Dimopoulos, MD¹⁸

¹Departments of Lymphoma/Myeloma and Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Hematology and Bone Marrow Transplantation Unit, General Hospital Evangelismos, Athens, Greece
³Department of Internal Medicine - Hematology, University Hospital, Prague, Czech Republic
⁴Department of Hematology, University General Hospital of Patras, Patras, Greece
⁵Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
⁶University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
⁷University Hospital Hôtel Dieu, Nantes, France
⁸Florida Cancer Specialists, Tallahassee Cancer Center, Tallahassee, FL
⁹Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
¹⁰Sarah Cannon Research Institute, Nashville, TN
¹¹Colorado Blood Cancer Institute, Sarah Cannon Research Institute, Denver, CO
¹²Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, Pierre-Benite, France
¹³Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
¹⁴Medical University of Silesia, Katowice, Poland
¹⁵Department of Hematological Oncology, Oncology Specialist Hospital, Brzozow, Poland
¹⁶Sarah Cannon Research Medical Center, Kansas City, MO
¹⁷Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
¹⁸National and Kapodistrian University of Athens, Athens, Greece

Hareth Nahi^1*, Saad Z. Usmani, MD MBA FACP², Maria-Victoria Mateos³, Niels W.C.J. van de Donk⁴, Philippe Moreau, MD, PhD^5*, Albert Oriol^6*, Torben Plesner, MD⁷, Nibedita Bandyopadhyay^8*, Peter Hellemans^9*, Brenda Tromp¹⁰, Ivo Nnane^8*, Donna Zemlickis^11*, Andrew Farnsworth^12* and Ajai Chari, MD^13*

¹Karolinska University Hospital at Huddinge, Karolinska Institute, Stockholm, Sweden
²Levine Cancer Institute, New York, NY
³University Hospital of Salamanca/IBSAL/Cancer Research Center- IBMCC (USAL-CSIC), Salamanca, Spain
⁴Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, Netherlands
⁵Hematology, University Hospital Hôtel-Dieu, Nantes, France
⁶Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
⁷Vejle Hospital and University of Southern Denmark, Vejle, Denmark
⁸Janssen Research & Development, LLC, Raritan, NJ
⁹Janssen Research & Development, Beerse, Belgium
¹⁰Janssen Research & Development, Leiden, Netherlands
¹¹Janssen Research & Development, LLC, Toronto, ON, Canada
¹²Janssen Research & Development, LLC, High Wycombe, United Kingdom
¹³Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY

Despina Fotiou, MD^1*, Ioannis V Kostopoulos, PhD^2*, Maria Krevvata, PhD^3*, Maria Gavriatopoulou, MD^1*, Ioannis Ntanasis-Stathopoulos, MD, MSc, PhD^1*, Pantelis Roussakis, MSc^2*, Chrysanthi Panteli^2*, Panagiotis Malandrakis, MD^1*, Magdalini Migkou, MD, PhD^1*, Nikolaos Kanellias, MD^1*, Evangelos Eleutherakis Papaiakovou, MD, MSc, PhD^1*, Foteini Theodorakakou, MD^1*, Evangelos Terpos, MD, PhD¹, Ourania E. Tsitsilonis, MD, PhD^2*, Meletios-Athanasios Dimopoulos, MD, PhD¹ and Efstathios Kastritis, MD^1*

¹Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
²Department of Biology, National and Kapodistrian University of Athens, School of Science, Athens, Greece
³Janssen Research & Development, LLC, Spring House, PA

Irene Manrique^1*, Richard Greil, MD², Johannes Andel, MD^3*, Siegfried Sormann^4*, Bernd L. Hartmann, MD^5*, Klaus Podar, MD, PhD⁶, Alexander Egle, MD², Andreas Petzer, Univ. Prof., MD⁷, Niklas Zojer, MD^8*, Eberhard Gunsilius, MD^9*, Reinhard Ruckser, MD¹⁰, Boris Bozic, MD^10*, Clemens A. Schmitt, MD¹¹, Sigrid Machherndl-Spandl^12*, Hermine Agis, MD¹³, Martin Schreder, MD^8*, Song-Yau Wang, MD^14*, Wolfgang Willenbacher, MD, PhD^9,15, Maria-Theresa Krauth, MD^13*, Christoph Tinchon, MD^16*, Michael Fillitz, MD^17*, Thomas Melchardt, Assoc. Prof., MD, PhD^2*, Stefan Knop^18*, Bruno Paiva, PhD^1* and Heinz Ludwig, MD¹⁹

¹Clinica Universidad de Navarra, Pamplona, Spain
²IIIrd Medical Department, Oncologic Center, Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster Salzburg, Salzburg, Austria
³Department of Internal Medicine II, LKH Steyr, Steyr, Austria
⁴Department of Internal Medicine, University Clinic Graz, Graz, AUT
⁵Department of Internal Medicine II, LKH Rankweil, Rankweil, Austria
⁶University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria
⁷Department of Internal Medicine I, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria
⁸Department of Medicine I, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria
⁹Department of Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria
¹⁰Department of Medicine II, Clinic Donaustadt, Vienna, Austria
¹¹Clinic for Internal Medicine 3, Kepler University Clinic Linz, Linz, Austria
¹²Department of Internal Medicine I, Ordensklinikum Linz Elisabethinen, Linz, Austria
¹³Department of Internal Medicine I, Divison of Hematology and Hemostaseology, Medical University Vienna, Vienna, Austria
¹⁴Department of Hematology, University Hospital of Leipzig, Leipzig, Germany
¹⁵Oncotyrol, Center for personalized Cancer Medicine, Innsbruck, Austria
¹⁶Department of Internal Medicine, LKH Hochsteiermark, Leoben, Austria
¹⁷Third Department of Internal Medicine, Hanusch Hospital, Vienna, Austria
¹⁸Division of Hematology and Medical Oncology, Department of Internal Medicine II, Wuerzburg University Medical Center, Wuerzburg, Germany
¹⁹Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria

Yifei Zhang, MD¹, Amandeep Godara, MD², Stacey Pan, MD^3*, Denis Toskic, BS^4*, Teresa Fogaren, NP^5*, Douglas W. Sborov, MD, MSc⁶, Raymond Comenzo, MD⁷ and Ankit Kansagra, MD⁸

¹Department of Medicine, Tufts Medical Center, Boston, MA
²Department of Hematology/Oncology, University of Utah, Salt Lake City, UT
³Tufts Medical, Boston, MA
⁴John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA
⁵Tufts Medical Center, Boston, MA
⁶Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
⁷Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA
⁸Blood and Marrow Transplant Program, University of Texas Southwestern Medical Center, Dallas, TX

Slavisa Ninkovic, MBBS^1,2, Nicholas E. Murphy, FRCPA, MBBS, FRACP^3,4, Hasib Sidiqi, MBBS⁵, Craig Thomas Wallington-Beddoe, BSc, MBBS, MBiostat, PhD, FRACP, FRCPA^6*, Anish Puliyayil, MD. DM. FRACP.^7*, Costas K. Yannakou, MBBS FRACP FRCPA^8*, Wojt Janowski, BMed BSc, FRCPA, FRACP⁹, Flora Yuen, BBiomedSc^10*, Andrew Spencer, MBBS, FRACP, FRCPA, DM¹¹ and Hang Quach, FRACP, FRCPA^12,13

¹Faculty of Medicine, University of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, VIC, Australia
²Department of Haematology, St. Vincent's Hospital Melbourne, Melbourne, VIC, Australia
³University of Tasmania, Hobart, Australia
⁴Royal Hobart Hospital, Hobart, Australia
⁵Department of Haematology, Fiona Stanley Hospital, Perth, Australia
⁶Flinders Medical Centre Flinders University, Adelaide, Australia
⁷Border Medical Oncology and Haematology, Albury-Wodonga Cancer Centre, Albury, Australia
⁸Department of Molecular Oncology and Cancer Immunology, Epworth HealthCare, East Melbourne, VIC, Australia
⁹Calvary Mater Newcastle, Waratah, AUS
¹⁰Department of Clinical Haematology, Alfred Hospital, Melbourne, Australia
¹¹Alfred Health - Monash University, Melbourne, Australia
¹²University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC, Australia
¹³St. Vincent’s Hospital, Melbourne, VIC, Australia

Evangelos Terpos, MD, PhD¹, Efstathios Kastritis, MD^1*, Evdoxia Hatjiharissi, MD^2*, Eirini Katodritou, MD^3*, Evangelos Eleutherakis Papaiakovou, MD, MSc, PhD^1*, Evgenia Verrou, MD^3*, Maria Gavriatopoulou, MD^1*, Alexandros Leonidakis, PhD^4*, Ioannis Ntanasis-Stathopoulos, MD^1*, Sosana Delimpasi, MD^5*, Marie-Christine Kyrtsonis, MD , PhD⁶, Maria Papaioannou^2*, Argiris Symeonidis, MD, PhD⁷ and Meletios A. Dimopoulos, MD¹

¹Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
²First Department of Internal Medicine, Division of Hematology, AHEPA University Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece
³Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece
⁴Health Data Specialists S.A., Athens, Greece
⁵Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece
⁶First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
⁷Hematology Division, Department of Internal Medicine, University of Patras, Medical School, Patras, Greece

Ashutosh D. Wechalekar^1,2,3,4*, John Silowsky, RN BSN^5*, Eileen Daniel^5*, Mark Harnett, MS^6*, Michael Spector, BS^7*, Susan B. Sobolov, PhD^5*, Candida Cristina Quarta, MD^8*, Michael R. Kurman, MD⁹, Mark Tulchinskiy, MD, MBA^10*, Amit Bhattacharyya, PhD^11* and Michaela Liedtke, MD¹²

¹National Amyloidosis Centre, London, United Kingdom
²University College London Hospitals NHS Foundation Trust, London, United Kingdom
³University College London and the Royal Free London NHS Foundation Trust, Division of Medicine, Faculty of Medical Sciences, London, United Kingdom
⁴National Amyloidosis Centre, University College London, London, United Kingdom
⁵Caelum Biosciences, Bordentown, NJ
⁶Caelum Biosciences, Stow, MA
⁷Caelum Biosciences, Shamong, NJ
⁸Alexion, AstraZeneca Rare Disease, Boston, MA
⁹Michael Kurman Consulting, LLC, Upper Saddle River, NJ
¹⁰IQVIA Biotech, Morrisville, NC
¹¹Alexion, AstraZeneca Rare Disease, Blue Bell, PA
¹²Division of Hematology, Department of Medicine, Stanford University, Stanford, CA

Alexander Lesokhin, MD^1,2, Shinsuke Iida, MD, PhD³, Don Stevens, MD⁴, Afshin Eli Gabayan, MD^5*, Wei Dong Ma^6*, Sharon Sullivan, PhD^7* and Marc-Steffen Raab^8*

¹Memorial Sloan Kettering Cancer Center, New York, NY
²Weill Cornell Medical College, New York, NY
³Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
⁴Norton Healthcare, Norton Cancer Institute, Louisville, KY
⁵Beverly Hills Cancer Center, Beverly Hills, CA
⁶Biostatistics, Pfizer Inc, New York, NY
⁷Pfizer Inc, Cambridge, MA
⁸Department of Hematology/Oncology, Heidelberg Myeloma Center, Heidelberg University Hospital, Heidelberg, Germany

Jesus Berdeja, MD¹, Sikander Ailawadhi, MD², Steven M. Horwitz, MD³, Jeffrey V. Matous, MD⁴, Neha Mehta-Shah, MD⁵, Thomas Martin, MD⁶, Eli Muchtar, MD⁷, Paul G. Richardson, MD⁸, Shambavi Richard^9*, Manisha Bhutani, MD¹⁰, Andrew J. Yee, MD¹¹, Michael R. Palmer, PhD^12*, Cathleen Gorman, MSc.^12*, Oliver Schoenborn-Kellenberger, MSc^12*, Sanela Bilic, PharmD, MBA^13*, Adam Crystal^12*, Michelle Mahler, MD¹² and Sagar Lonial, MD, FACP¹⁴

¹Tennessee Oncology (Sarah Cannon Research Institute), Nashville, TN
²Division of hematology, Mayo Clinic, Jacksonville, FL
³Memorial Sloan Kettering Cancer Center, New York, NY
⁴Sarah Cannon Research Institute, Colorado Blood Cancer Institute, Denver, CO
⁵Washington University in St. Louis, Department of Medicine, Division of Hematology/Oncology, St. Louis, MO
⁶University of California San Francisco, San Francisco, CA
⁷Division of Hematology, Mayo Clinic Rochester, Saint Paul, MN
⁸Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
⁹Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
¹⁰Levine L. Cancer Institute, Charlotte, NC
¹¹Massachusetts General Hospital Cancer Center, Boston, MA
¹²C4 Therapeutics, Watertown, MA
¹³Vanadro Consulting Inc, Watertown, MA
¹⁴Winship Cancer Institute, Emory University, Atlanta, GA

Parameswaran Hari¹, Jesus G. Berdeja², Valerio De Stefano^3*, Francesca Gay, MD, PhD^4*, Becky Hooper^5*, Anja Haltner^5*, Shaji K Kumar, MD⁶, Thomas Martin, MD⁷, Maria-Victoria Mateos⁸, Philippe Moreau, MD, PhD^9*, Emily Rosta^5*, Imtiaz A. Samjoo^10*, Saad Z. Usmani, MD MBA FACP¹¹, Katja Weisel^12*, Carolyn C. Jackson^13*, Yunsi Olyslager^14*, Jordan M. Schecter¹³, Martin Vogel^15*, Ashraf Garrett^16*, Sam Lee^16*, Tonia Nesheiwat^16*, Lida Pacaud^16*, Changwei Zhou^16*, Satish Valluri, PhD^15*, Luciano J. Costa, MD, PhD¹⁷ and Yi Lin⁶

¹Medical College of Wisconsin, Milwaukee, WI
²Sarah Cannon Research Institute, Nashville, TN
³Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A Gemelli, IRCCS, Rome, Italy
⁴Division of Hematology, University of Torino, Torino, Italy
⁵EVERSANA, Sydney, NS, Canada
⁶Mayo Clinic, Rochester, MN
⁷UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
⁸Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca, Spain
⁹Clinical Hematology, University Hospital Hotel-Dieu, Nantes, France
¹⁰EVERSANA, Burlington, ON, Canada
¹¹Levine Cancer Institute, New York, NY
¹²University Medical Center Hamburg-Eppendorf, Hamburg, Germany
¹³Janssen R&D, Raritan, NJ
¹⁴Janssen Pharmaceutica NV, Beerse, Belgium
¹⁵Janssen Global Services, LLC., Raritan, NJ
¹⁶Legend Biotech USA, Piscataway, NJ
¹⁷University of Alabama at Birmingham, Birmingham, AL

Paula Rodríguez-Otero, MD, PhD^1*, Veronica Gonzalez De La Calle, MD, PhD^2*, Anna Sureda³, Felipe De Arriba, PhD^4*, Marta Reinoso Segura^5*, Paz Ribas^6*, Ana Pilar Gonzalez, PhD^7*, Yolanda Gonzalez-Montes^8*, Albert Oriol^9*, Joaquín Martínez-López^10*, Marta Sonia Gonzalez, MD^11*, Miguel T Hernández, MD, PhD^12*, Maialen Sirvent^13*, Joan Bladé Creixenti¹⁴, Juan Jose Lahuerta, MD, PhD^15*, Jesús F. San-Miguel¹ and Maria-Victoria Mateos¹⁶

¹Clínica Universidad de Navarra, Pamplona, Spain
²Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
³Institut Català D'Oncologia, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain
⁴Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
⁵Instituto de Biomedicina de Sevilla (IBiS), UGC-Hematología, Hospital Universitario Virgen del Rocío/ CSIC/ CIBERONC, Universidad de Sevilla, Sevilla, Spain
⁶Hospital Dr. Peset, Valencia, Spain
⁷Hospital Central de Asturias, Oviedo, Spain
⁸Institut d’Oncologia Dr. Josep Trueta, Girona, Spain
⁹Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain
¹¹Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
¹²Department of Hematology, Hospital Universitario de Canarias, La Laguna, Spain
¹³Hospital Universitario de Donostia, San Sebastián, Spain
¹⁴Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain
¹⁵Hospital Doce de Octubre, CIBERONC, Madrid, Spain
¹⁶Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain

Wee-Joo Chng, MBBS, PhD, FRCPath, FRCP¹, Sagar Lonial, MD, FACP², Gareth J. Morgan^3*, Shinsuke Iida, MD, PhD⁴, Philippe Moreau, MD, PhD^5*, Shaji K Kumar, MD⁶, Philip Twumasi-Ankrah^7*, Arun Kumar^7*, Ajeeta B. Dash, PhD^7*, Alexander Vorog, MD^8*, Xiaoquan Zhang, MD^7*, Kaveri Suryanarayan, MD^7*, Richard Labotka, MD⁷, Meletios A. Dimopoulos, MD⁹ and S. Vincent Rajkumar, MD^6*

¹Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
²Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University Medical School, Emory University, Atlanta, GA
³Perlmutter Cancer Center, NYU Langone Health, New York, NY
⁴Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
⁵Hematology Department, University Hospital Hotel Dieu, Nantes, France
⁶Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
⁷Takeda Development Center Americas, Inc. (TDCA), Lexington, MA
⁸Takeda Development Center Americas, Inc., Lexington, MA
⁹National and Kapodistrian University of Athens, Athens, Greece

Paul G. Richardson, MD^1,2, Ruben Niesvizky, MD³, Jay Yang, PhD^4*, Neelu Yadav, PhD^4*, Helen Hsu, MD^4* and Christopher R. Flowers⁵

¹Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
⁴Epizyme, Inc., Cambridge, MA
⁵Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX

Shaji K Kumar, MD¹, Admasu Mamuye, MD, MSc^2*, Kristina Dabovic, PharmD^3*, Jingyuan Wang, PhD^3*, Banmeet Anand, PhD^4*, Amy Yuet, PhD^4*, Bhagirathbhai Dholaria, MBBS⁵ and Vivek Roy, MD⁶

¹Mayo Clinic, Rochester, MN
²Molecular Templates, Inc., New York, NY
³Molecular Templates, Inc., Jersey City, NJ
⁴Molecular Templates, Inc., Austin, TX
⁵Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
⁶Mayo Clinic, Jacksonville, FL